Kidneys Home > Inlyta and Breastfeeding
It is unknown if Inlyta (axitinib) passes through human breast milk or if it would harm a baby who was breastfeeding. Inlyta is not usually recommended for use in women who are nursing. However, if you do breastfeed while using this drug, watch for problems in your child, such as diarrhea, vomiting, or difficulty feeding, and immediately report them to your child's healthcare provider.
Can Breastfeeding Women Take Inlyta?Inlyta® (axitinib) is a prescription medication used to treat advanced renal cell carcinoma (kidney cancer) after at least one other medication has been tried but failed. It is unknown whether the drug passes through breast milk. Therefore, if you are breastfeeding or plan to start, talk to your healthcare provider before taking Inlyta.
More Information About Inlyta and BreastfeedingThere is very little information available on the use of Inlyta during breastfeeding. The medication has not been studied in breastfeeding women, so it is unknown whether it would pass through breast milk or harm a nursing infant.
Although this lack of information is certainly frustrating, it is important to remember that medications are rarely studied in women who are nursing. This is because such studies would expose an infant, who would otherwise not benefit from use of the medication, to potential harm.
The manufacturer of Inlyta recommends women either breastfeed or use Inlyta, but not do both. If your healthcare provider does recommend using this drug while breastfeeding, make sure to observe your child closely for any possible Inlyta side effects, and report any problems to your child's healthcare provider. Some of these problems could include but are not limited to:
- Unusual tiredness
- Lack of appetite or difficulty feeding
- Unusual bruising or bleeding.